A
ACRS icon

AJOVista’s Aclaris Therapeutics ACRS Stock Holding History

AJOVista’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$20.1K Buy
+17,455
New +$21.4K 0.09% 110

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AJOVista's ACRS Position: Q3 2024 in Review

AJOVista opened a new position in Aclaris Therapeutics (ACRS) in Q3 2024: 17,455 shares worth $20.1K. The stake represents 0.09% of the portfolio and ranks #110 among its holdings.

81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • AJOVista held 17,455 shares of Aclaris Therapeutics worth $20.1K as of Q3 2024.
  • Aclaris Therapeutics was a new AJOVista position in Q3 2024.
  • Aclaris Therapeutics made up 0.09% of AJOVista's portfolio in Q3 2024, its #110 holding.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on AJOVista's 13F filing for Q3 2024, filed 12 Nov 2024.